163 related articles for article (PubMed ID: 18330580)
1. Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up.
Suppiah A; Alabi A; Madden L; Hartley JE; Monson JR; Greenman J
Int J Colorectal Dis; 2008 Jun; 23(6):595-600. PubMed ID: 18330580
[TBL] [Abstract][Full Text] [Related]
2. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival.
Shiota G; Ishida M; Noguchi N; Oyama K; Takano Y; Okubo M; Katayama S; Tomie Y; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Kanbe T; Tanaka K; Nosaka K; Tanida O; Kojo H; Miura K; Ito H; Kaibara N; Kawasaki H
Dig Dis Sci; 2000 Jan; 45(1):122-8. PubMed ID: 10695624
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
[TBL] [Abstract][Full Text] [Related]
4. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
[TBL] [Abstract][Full Text] [Related]
5. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
[TBL] [Abstract][Full Text] [Related]
6. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.
Gervaz P; Bouzourene H; Cerottini JP; Chaubert P; Benhattar J; Secic M; Wexner S; Givel JC; Belin B
Dis Colon Rectum; 2001 Mar; 44(3):364-72; discussion 372-3. PubMed ID: 11289282
[TBL] [Abstract][Full Text] [Related]
7. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer.
Kressner U; Glimelius B; Bergström R; Påhlman L; Larsson A; Lindmark G
Br J Cancer; 1998 Jun; 77(11):1848-51. PubMed ID: 9667657
[TBL] [Abstract][Full Text] [Related]
8. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients.
Yamaguchi T; Takii Y; Maruyama S
Surg Today; 2014 Aug; 44(8):1529-35. PubMed ID: 23975589
[TBL] [Abstract][Full Text] [Related]
10. Increased p53 protein content of colorectal tumours correlates with poor survival.
Remvikos Y; Tominaga O; Hammel P; Laurent-Puig P; Salmon RJ; Dutrillaux B; Thomas G
Br J Cancer; 1992 Oct; 66(4):758-64. PubMed ID: 1419618
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients.
Daitoku N; Miyamoto Y; Sakamoto Y; Tokunaga R; Hiyoshi Y; Nagai Y; Iwatsuki M; Iwagami S; Yoshida N; Baba H
Int J Clin Oncol; 2020 Apr; 25(4):651-659. PubMed ID: 31834556
[TBL] [Abstract][Full Text] [Related]
12. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of colorectal cancer.
Fan CW; Kuo YB; Lin GP; Chen SM; Chang SH; Li BA; Chan EC
Clin Chim Acta; 2017 Dec; 475():157-163. PubMed ID: 29074220
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.
Abendstein B; Marth C; Müller-Holzner E; Widschwendter M; Daxenbichler G; Zeimet AG
Cancer; 2000 Mar; 88(6):1432-7. PubMed ID: 10717627
[TBL] [Abstract][Full Text] [Related]
14. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma.
Giatromanolaki A; Stathopoulos GP; Tsiompanou E; Papadimitriou C; Georgoulias V; Gatter KC; Harris AL; Koukourakis MI
Cancer; 1999 Oct; 86(8):1421-30. PubMed ID: 10526268
[TBL] [Abstract][Full Text] [Related]
15. Anti-p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta-analysis.
Liu S; Tan Q; Song Y; Shi Y; Han X
Scand J Immunol; 2020 Feb; 91(2):e12829. PubMed ID: 31536647
[TBL] [Abstract][Full Text] [Related]
16. A specific autoantibody against a novel tumour-association antigen derived from human DNA-topoiomerase I is a potential biomarker for early diagnosis and favourable prognosis in patients with colorectal carcinoma.
Zhao F; Cao M; Jiang XH; Xie K; Ye SR; Yie SM
Biomarkers; 2020 Mar; 25(2):149-156. PubMed ID: 31922440
[No Abstract] [Full Text] [Related]
17. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients.
Horiuchi A; Iinuma H; Akahane T; Shimada R; Watanabe T
Oncol Rep; 2012 May; 27(5):1384-92. PubMed ID: 22267128
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]